Drug Detail

Information about figitumuab

Generic Name	figitumuab
IND	CP 751,871
Brand Name (US)
Manufacturer	Pfizer
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Development discontinued
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

Note: We understand that Pfizer has stopped development of this drug.

This is a IGF1R inhibitor that is being dropped from development.
IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs. Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.